The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography

被引:78
作者
Efrati, S [1 ]
Dishy, V
Averbukh, M
Blatt, A
Krakover, R
Weisgarten, J
Morrow, JD
Stein, MC
Golik, A
机构
[1] Assaf Harofeh Med Ctr, Dept Med A, Div Cardiol, IL-70300 Zerifin, Israel
[2] Assaf Harofeh Med Ctr, Div Nephrol, IL-70300 Zerifin, Israel
[3] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA
关键词
N-acetylcysteine; contrast media; renal failure; nitric oxide; oxidative stress;
D O I
10.1046/j.1523-1755.2003.00322.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Renal failure induced by radiographic contrast agents is a known complication of coronary angiography, especially among patients with chronic renal failure. Recently, treatment with N-acetylcysteine (NAC) has been shown to have a protective effect but the mechanisms are unknown. We examined the hypothesis that NAC protected against contrast-induced renal impairment through effects on nitric oxide metabolism and oxidative stress. Methods. Patients with a serum creatinine concentration above 106 mumol/L undergoing coronary angiography were randomly assigned to receive either NAC 1 g (N = 24) or placebo (N = 29) twice daily 24 hours before and after angiography with 0.45% saline hydration in a double-blind study. Creatinine clearance was calculated and urinary nitric oxide and F2-isoprostane excretion were measured at baseline, 24 and 96 hours after angiography. Results. Treatment with NAC significantly improved the effect of contrast media on creatinine clearance, and maximal beneficial effect was observed 24 hours after angiography. Creatinine clearance (mL/min) was 59.5 +/- 4.4, 64.7 +/- 5.8, and 58.7 + 3.9 at baseline, 24, and 96 hours after angiography in the NAC group, respectively, and 65.2 +/- 3.2, 51.5 +/- 3.7, and 53.6 +/- 3.9 in the placebo group, respectively (P < 0.0001). NAC treatment prevented the reduction in urinary nitric oxide after angiography. The urinary nitric oxide/creatinine ratio (mol/mg) was 0.0058 +/- 0.0004, 0.0057 +/- 0.0004, and 0.0052 +/- 0.0004 at baseline, 24, and 96 hours after angiography in NAC group, respectively, and 0.0057 +/- 0.0007, 0.0031 +/- 0.0005, and 0.0039 +/- 0.0005 in the placebo group, respectively (P = 0.013). NAC had no significant effect on urinary F2-isoprostanes. Conclusion. NAC treatment has renoprotective effect in patients with mild chronic renal failure undergoing coronary angiography that may be mediated in part by an increase in nitric oxide production.
引用
收藏
页码:2182 / 2187
页数:6
相关论文
共 38 条
[1]   NITRIC-OXIDE AND PROSTANOIDS PROTECT THE RENAL OUTER MEDULLA FROM RADIOCONTRAST TOXICITY IN THE RAT [J].
AGMON, Y ;
PELEG, H ;
GREENFELD, Z ;
ROSEN, S ;
BREZIS, M .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1069-1075
[2]  
BARRETT BJ, 1994, J AM SOC NEPHROL, V5, P125
[3]   Low nitric oxide production in patients with chronic renal failure [J].
Blum, M ;
Yachnin, T ;
Wollman, Y ;
Chernihovsky, T ;
Peer, G ;
Grosskopf, I ;
Kaplan, E ;
Silverberg, D ;
Cabili, S ;
Iaina, A .
NEPHRON, 1998, 79 (03) :265-268
[4]   PHARMACOKINETICS OF N-ACETYLCYSTEINE IN MAN [J].
BORGSTROM, L ;
KAGEDAL, B ;
PAULSEN, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :217-222
[5]   Acetylcysteine and contrast agent-associated nephrotoxicity [J].
Briguori, C ;
Manganelli, F ;
Scarpato, P ;
Elia, PP ;
Golia, B ;
Riviezzo, G ;
Lepore, S ;
Librera, M ;
Villari, B ;
Colombo, A ;
Ricciardelli, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :298-303
[6]   DOSING OF CONTRAST MATERIAL TO PREVENT CONTRAST NEPHROPATHY IN PATIENTS WITH RENAL-DISEASE [J].
CIGARROA, RG ;
LANGE, RA ;
WILLIAMS, RH ;
HILLIS, LD .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) :649-652
[7]   N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure [J].
Conesa, EL ;
Valero, F ;
Nadal, JC ;
Fenoy, FJ ;
López, B ;
Arregui, B ;
Salom, MG .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (03) :R730-R737
[8]   Acetylcysteine to prevent angiography-related renal tissue injury (the APART Trial) [J].
Diaz-Sandoval, LJ ;
Kosowsky, BD ;
Losordo, DW .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (03) :356-+
[9]   N-acetyl cysteine ameliorates ischemic renal failure [J].
DiMari, J ;
Megyesi, J ;
Udvarhelyi, N ;
Price, P ;
Davis, R ;
Safirstein, R .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1997, 272 (03) :F292-F298
[10]   A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography [J].
Durham, JD ;
Caputo, C ;
Dokko, J ;
Zaharakis, T ;
Pahlavan, M ;
Keltz, J ;
Dutka, P ;
Marzo, K ;
Maesaka, JK ;
Fishbane, S .
KIDNEY INTERNATIONAL, 2002, 62 (06) :2202-2207